Phio Pharmaceuticals Corp. (NASDAQ: PHIO) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT PHIO PHARMACEUTICALS CORP.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
Listen to this Section


$1.13
+0.0150 ( +1.35% ) 69.8K

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Clinical Trial Pipeline Stages


Drug Name Stage
PH-762DetailsCutaneous squamous cell carcinoma, Melanoma, Metastatic merkel cell carcinoma, Cancer Phase 1b

Market Data


Open $1.13
Previous Close $1.11
Volume 69.8K
Market Cap $12.90M
Day Range $1.11 - $1.14
52 Week Range $0.81 - $4.19
Shares Outstanding 11.62M
Change % +1.35%
Net Change ▲ 0.0150
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2012
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: 12,286.00

Date Type Amount Purchased Purchaser
2025-06-11 Buy 2000.00 Bitterman Robert J
2025-06-11 Buy 2500.00 Ferrara Robert L
2025-06-10 Buy 1500.00 Bitterman Robert J
2025-05-23 Buy 3000.00 Bitterman Robert J
2025-05-21 Buy 2500.00 Ferrara Robert L
2024-06-11 Buy 1000.00 Bitterman Robert J
2024-06-10 Buy 1000.00 Bitterman Robert J
2024-03-05 Sale -335.00 Kontulis Caitlin
2024-02-27 Buy 2500.00 Bitterman Robert J
2024-02-22 Sale -1804.00 Bitterman Robert J

SEC Filings


Form Type Description Pages Date
4 Insider transactions 2 Sep 15, 2025
4 Insider transactions 2 Sep 15, 2025
4 Insider transactions 2 Sep 15, 2025
4 Insider transactions 2 Sep 15, 2025
8-k 8K-related 14 Sep 03, 2025
8-k 8K-related 14 Aug 14, 2025
10-q Quarterly Reports 59 Aug 14, 2025
def Proxies and info statements 19 Jul 30, 2025
ars Annual reports 1 Jul 30, 2025
8-k 8K-related 16 Jul 30, 2025

Latest News


× Before browsing our site, please accept our cookies policy